Investigators retrospectively assessed whether previous TKI therapy may affect response and survival outcomes in patients with relapsed or refractory acute myeloid leukemia.
Study results suggest that flotetuzumab demonstrates antileukemic activity in patients with primary induction failure and early-relapse acute myeloid leukemia.
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).
Hypogammaglobulinemia often occurs in patients with chronic lymphocytic leukemia who receive CAR-T, but there is no standard way to manage it.
Patients with AML or MDS were significantly more likely to die from COVID-19 vs other HMs. Most treatments did not improve survival outcomes — except corticosteroids.
Now that the phase 2 dose is established, a randomization cohort will test the efficacy of the treatments in the LACEWING trial.
Census tract affluence, disadvantage, and segregation were all significant predictors of leukemia-related death.
